Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.

Sit D, Perel JM, Luther JF, Wisniewski SR, Helsel JC, Wisner KL.

J Clin Psychopharmacol. 2010 Aug;30(4):381-6. doi: 10.1097/JCP.0b013e3181e7be23.

2.

Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.

Kim J, Riggs KW, Misri S, Kent N, Oberlander TF, Grunau RE, Fitzgerald C, Rurak DW.

Br J Clin Pharmacol. 2006 Feb;61(2):155-63.

3.

Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Sit DK, Perel JM, Helsel JC, Wisner KL.

J Clin Psychiatry. 2008 Apr;69(4):652-8.

4.

Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.

Blázquez A, Mas S, Plana MT, Gassó P, Méndez I, Torra M, Arnaiz JA, Lafuente A, Lázaro L.

J Clin Psychopharmacol. 2014 Jun;34(3):318-26. doi: 10.1097/JCP.0000000000000121.

PMID:
24743718
5.

Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.

Burke WJ, Hendricks SE, McArthur-Miller D, Jacques D, Bessette D, McKillup T, Stull T, Wilson J.

J Clin Psychopharmacol. 2000 Aug;20(4):423-7.

PMID:
10917403
6.

Therapeutic drug monitoring of children and adolescents treated with fluoxetine.

Koelch M, Pfalzer AK, Kliegl K, Rothenhöfer S, Ludolph AG, Fegert JM, Burger R, Mehler-Wex C, Stingl J, Taurines R, Egberts K, Gerlach M.

Pharmacopsychiatry. 2012 Mar;45(2):72-6. doi: 10.1055/s-0031-1291294. Epub 2011 Nov 15.

PMID:
22086744
7.

Fluoxetine once every third day in the treatment of major depressive disorder.

Tural U, Onder E.

Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):307-12.

PMID:
14714120
8.

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P.

J Clin Psychopharmacol. 2001 Jun;21(3):330-4.

PMID:
11386497
9.

Fluoxetine pharmacokinetics in pediatric patients.

Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N, Sinha V.

J Clin Psychopharmacol. 2002 Dec;22(6):568-75.

PMID:
12454556
10.

Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL.

J Clin Psychiatry. 2011 Jul;72(7):994-1001. doi: 10.4088/JCP.10m06461.

11.
12.

[Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day].

Bourdeaux R, Pannetier P, Younos C, Desor D, Lehr PR, Capolaghi B.

Encephale. 1998 Jan-Feb;24(1):57-61. French.

PMID:
9559305
13.

Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.

Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.

Psychiatry Clin Neurosci. 2011 Aug;65(5):510-7. doi: 10.1111/j.1440-1819.2011.02235.x.

14.

Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.

Kandasamy M, Tripathy K, Ravi S, Kamath N, Pai B, Srinivas NR, Kristjansson F, Thangam S.

Arzneimittelforschung. 2010;60(1):12-21. doi: 10.1055/s-0031-1296243.

PMID:
20184222
15.

Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).

Shoulson RL, Stark RL, Garland M.

J Am Assoc Lab Anim Sci. 2014 Nov;53(6):708-16.

16.

Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.

Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.

Clin J Pain. 2011 Nov-Dec;27(9):805-10. doi: 10.1097/AJP.0b013e3182201849.

PMID:
21677571
17.

Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.

J Psychopharmacol. 2002 Sep;16(3):215-9.

PMID:
12236627
18.

Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.

Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.

J Ment Health Policy Econ. 2010 Mar;13(1):27-35.

PMID:
20571180
19.

Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T.

Biol Psychiatry. 2006 Jun 1;59(11):1052-60. Epub 2006 Apr 3.

PMID:
16581036
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk